Health · Pharma & Biotech · 1 day ago
Wegovy obesity tablets to go on sale in France on 2 November
Wegovy tablets will go on sale in France on 2 November as a new option for treating obesity.
Wegovy is made by Danish drugmaker Novo Nordisk and contains semaglutide, a medicine that can reduce appetite and help people lose weight.
The tablets add an alternative to weekly injections, which were already available on prescription.
A month of tablets will cost €169, but France’s public health insurance will not cover them.
Novo Nordisk says about 100,000 people in France use Wegovy, and around 30% would prefer tablets to injections.
Prescriptions require medical advice, and France’s health authority recommends that a specialist in obesity care be consulted.
The company has not applied for reimbursement, while the medicines agency has reported dozens of serious side-effect cases linked to improper use.
Wegovy obesity tablets are due to become available in French pharmacies on 2 November 2026.
The tablets contain semaglutide, a GLP-1 medicine that controls blood sugar and helps reduce weight.
They will require a prescription and will not be covered by France’s national health insurance.
Novo Nordisk France says a month’s treatment will cost €169, similar to the injectable version.
The French medicines agency has reported dozens of serious adverse-effect cases linked to misuse of Wegovy.
- Who
- Novo Nordisk’s Wegovy, a semaglutide medicine for people with obesity.
- What
- Wegovy tablets are to go on sale in pharmacies. They will require a prescription and will not be reimbursed by national health insurance.
- When
- 2 November 2026.
- Where
- Pharmacies in France.
- Why
- The tablets offer an alternative to weekly injections; a report says about 30% of current Wegovy patients would prefer tablets.
This story does not have two clearly opposing sides.
Wegovy was available in France only as a prescription injection.
Wegovy tablets are due to become available in French pharmacies.
- Availability
- 2 November 2026
- Price
- €169 for one month of tablets
- Reimbursement
- Tablets are not covered by France’s national health insurance
- Patient estimate
- About 100,000 people in France are treated with Wegovy
- Tablet preference
- About 30% of current patients would prefer tablets to weekly injections
3 sources
What people are saying
A price similar to the injectable treatment
semaglutide should only be prescribed after advice from a specialist in the treatment of obesity